Kevin Outterson
Profiles

Kevin Outterson, JD, LLM

Professor of Health Law, Ethics & Human Rights, Health Law, Policy & Management - Boston University School of Public Health

(617) 358-2047
mko@bu.edu
Talbot
View Full Profile at BUMC

Biography

Research interests in pharmaceutical innovation, including the law & economics of antimicrobial resistance.

Other Positions

  • Professor of Law and N. Neal Pike Scholar, Health and Disability Law - Boston University School of Law
  • Executive Director of CARB-X, Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) - Boston University School of Law

Education

  • Northwestern University School of Law, JD Field of Study: Law
  • University of Cambridge, LLM Field of Study: Law
  • Northwestern University, BS Field of Study: History/Rhetoric

Websites

Publications

  • Published on 11/28/2024

    Goh M, Kesselheim AS, Outterson K. Azithromycin to Reduce Mortality. N Engl J Med. 2024 Nov 28; 391(21):2060. PMID: 39602642.

     Read At: PubMed
  • Published on 9/20/2024

    Balasegaram M, Outterson K, Røttingen JA. The time to address the antibiotic pipeline and access crisis is now. Lancet. 2024 Oct 12; 404(10461):1385-1387. PMID: 39312929.

     Read At: PubMed
  • Published on 6/14/2024

    Anderson M, Towse A, Outterson K, Mossialos E. Implementing an EU pull incentive for antimicrobial innovation and access: blueprint for action. Lancet Microbe. 2024 Oct; 5(10):100886. PMID: 38885690.

     Read At: PubMed
  • Published on 5/23/2024

    Laxminarayan R, Impalli I, Rangarajan R, Cohn J, Ramjeet K, Trainor BW, Strathdee S, Sumpradit N, Berman D, Wertheim H, Outterson K, Srikantiah P, Theuretzbacher U. Expanding antibiotic, vaccine, and diagnostics development and access to tackle antimicrobial resistance. Lancet. 2024 Jun 08; 403(10443):2534-2550. PMID: 38797178.

     Read At: PubMed
  • Published on 3/1/2023

    Madden J, Outterson K. Trends in the global antibiotics market. Nat Rev Drug Discov. 2023 Mar; 22(3):174. PMID: 36792692.

     Read At: PubMed
  • Published on 2/11/2023

    Outterson K, Rex JH. Global Pull Incentives for Better Antibacterials: The UK Leads the Way. Appl Health Econ Health Policy. 2023 May; 21(3):361-364. PMID: 36773115.

     Read At: PubMed
  • Published on 4/9/2022

    Outterson K, Orubu ESF, Rex J, Årdal C, Zaman MH. Patient Access in 14 High-Income Countries to New Antibacterials Approved by the US Food and Drug Administration, European Medicines Agency, Japanese Pharmaceuticals and Medical Devices Agency, or Health Canada, 2010-2020. Clin Infect Dis. 2022 Apr 09; 74(7):1183-1190. PMID: 34251436.

     Read At: PubMed
  • Published on 1/1/2022

    Van Katwyk SR, Outterson K. Introduction: AMR Belongs in the Pandemic Instrument. J Law Med Ethics. 2022; 50(S2):6-8. PMID: 36889349.

     Read At: PubMed
  • Published on 1/1/2022

    Weldon I, Liddell K, Van Katwyk SR, Hoffman SJ, Minssen T, Outterson K, Palmer S, Viens AM, Viñuales J. A Pandemic Instrument Can Start Turning Collective Problems into Collective Solutions by Governing the Common-Pool Resource of Antimicrobial Effectiveness. J Law Med Ethics. 2022; 50(S2):17-25. PMID: 36889344.

     Read At: PubMed
  • Published on 12/6/2021

    Rex JH, Outterson K. Antibacterial R&D at a Crossroads: We've Pushed as Hard as We Can … Now We Need to Start Pulling! Clin Infect Dis. 2021 12 06; 73(11):e4451-e4453. PMID: 32584949.

     Read At: PubMed

View 83 more publications:View Full Profile at BUMC

News & In the Media

View all profiles